Myeloid-Derived Suppressor Cells and Radiotherapy

Area of Science:

• Oncology
• Immunology
• Radiotherapy

Background:

• Myeloid-derived suppressor cells (MDSC) are immature myeloid cells with potent immunosuppressive functions.
• MDSC expansion is associated with cancer progression and treatment resistance in preclinical models and patients.
• MDSCs represent promising targets for novel immunotherapeutic strategies.

Purpose of the Study:

• To review preclinical and clinical evidence on MDSCs' impact on radiotherapy (RT) efficacy.
• To discuss the potential of MDSC-targeting strategies to improve RT-mediated tumor control.

Main Methods:

• Literature review of preclinical studies.
• Analysis of clinical evidence.
• Critical discussion of MDSC-targeting strategies in combination with RT.

Main Results:

• MDSCs have been shown to negatively impact the efficacy of radiotherapy.
• Evidence suggests MDSCs contribute to accelerated disease progression and treatment resistance in cancer.

Conclusions:

• MDSC-targeting strategies hold potential for enhancing immunotherapy outcomes when combined with RT.
• Combining MDSC-targeting approaches with RT may lead to superior immunotherapeutic tumor control in clinical settings.